Literature DB >> 2278060

Parenteral sulphadoxine-pyrimethamine (Fansidar): an effective and safe but under-used method of anti-malarial treatment.

L A Salako1, R A Adio, A Sowunmi, O Walker.   

Abstract

One hundred and eighteen patients with acute falciparum malaria were randomized into treatment with either intramuscular or oral sulfadoxine-pyrimethamine (Fansidar, Roche) and the results were compared with those from 68 patients treated in parallel with chloroquine. Parasitological cure rate was 97% with oral sulfadoxine-pyrimethamine, 95% with the injection, and only 63% with chloroquine. The time for the disappearance of parasitaemia in sensitive cases was the same with oral and intramuscular sulfadoxine-pyrimethamine and shorter than with chloroquine. Side effects occurred in only 3 of the patients treated with intramuscular sulfadoxine-pyrimethamine compared with 8 of those treated with the tablets and 13 of those treated with chloroquine. The results showed that intramuscular sulfadoxine-pyrimethamine is as effective as, and probably better tolerated than, the oral drug. Increasing failure of response to chloroquine in Nigeria was also demonstrated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278060     DOI: 10.1016/0035-9203(90)90131-w

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  3 in total

Review 1.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

2.  The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.

Authors:  P A Winstanley; W M Watkins; C R Newton; C Nevill; E Mberu; P A Warn; C M Waruiru; I N Mwangi; D A Warrell; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

3.  How frequent are notified severe cutaneous adverse reactions to Fansidar?

Authors:  D Stürchler; M L Mittelholzer; L Kerr
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.